Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.43 |
| ▸ | FLT4 | P35916 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120456 | 0.91 | GPR119 (0.55) | EIF4EMKNK1MKNK2GPR119FGFR1 | |
| SCHEMBL10120666 | 0.90 | GPR119 (0.59) | EIF4EMKNK1MKNK2GPR119 | |
| SCHEMBL10120507 | 0.88 | GPR119 (0.51) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10105772 | 0.84 | KDR (0.52) | EIF4EMKNK1MKNK2GPR119FGFR1 | |
| SCHEMBL10105774 | 0.83 | GPR119 (0.46) | EIF4EMKNK1MKNK2GPR119FGFR1 | |
| SCHEMBL10105795 | 0.81 | GPR119 (0.40) | EIF4EMKNK1MKNK2GPR119EGFR | |
| SCHEMBL10134277 | 0.81 | GPR119 (0.49) | GPR119FGFR1FLT1FLT4KDR | |
| SCHEMBL10108025 | 0.81 | GPR119 (0.43) | EIF4EMKNK1MKNK2GPR119FGFR1 | |
| SCHEMBL10120519 | 0.80 | GPR119 (0.58) | MKNK2GPR119FGFR1FLT1FLT4 | |
| SCHEMBL10108022 | 0.80 | GPR119 (0.43) | EIF4EMKNK1MKNK2GPR119FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | EIF4E 3412/4885MKNK1 1553/4885MKNK2 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.